From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization
Mark K. Schlegel(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Patrick Haslett, Lauren Blair Woods(Alnylam Pharmaceuticals (United States)), Sarah Hyde(Alnylam Pharmaceuticals (United States)), Svetlana Shulga‐Morskaya(Alnylam Pharmaceuticals (United States)), Maja M. Janas(Alnylam Pharmaceuticals (United States)), Tara Mayo(Alnylam Pharmaceuticals (United States)), Sally Schofield(Alnylam Pharmaceuticals (United States)), Vasant Jadhav(Alnylam Pharmaceuticals (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Abigail Liebow(Alnylam Pharmaceuticals (United States)), Adam Castoreno(Alnylam Pharmaceuticals (United States)), Daniel Berman(Alnylam Pharmaceuticals (United States)), Joseph D. Barry(Dana-Farber Cancer Institute), John Szeto(Alnylam Pharmaceuticals (United States)), Christopher R. Brown(Alnylam Pharmaceuticals (United States)), Saket Agarwal(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Tuyen Nguyen(Alnylam Pharmaceuticals (United States)), Stuart Milstein(Alnylam Pharmaceuticals (United States)), Martin Egli(Vanderbilt University), Yongfeng Jiang(Alnylam Pharmaceuticals (United States)), Wendell Davis(Alnylam Pharmaceuticals (United States)), Kevin Fitzgerald(Epsilon Systems (United States)), Sarah LeBlanc(Alnylam Pharmaceuticals (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Vedat O. Yilmaz(Alnylam Pharmaceuticals (United States))
Cited by 93
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k